Fennec Pharmaceuticals Inc. (FENC)
Largest Insider Buys in Sector
FENC Stock Price History Chart
FENC Stock Performance
About Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Insider Activity of Fennec Pharmaceuticals Inc.
Over the last 12 months, insiders at Fennec Pharmaceuticals Inc. have bought $0 and sold $3.74M worth of Fennec Pharmaceuticals Inc. stock.
On average, over the past 5 years, insiders at Fennec Pharmaceuticals Inc. have bought $2.65M and sold $1.58M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 29,167 shares for transaction amount of $0 was made by Raykov Rosty (CHIEF EXECUTIVE OFFICER) on 2024‑04‑01.
List of Insider Buy and Sell Transactions, Fennec Pharmaceuticals Inc.
| 2024-11-04 | Sale | director | 2,431 0.0082% | $4.31 | $10,478 | -6.24% | ||
| 2024-10-08 | Sale | director | 1,406 0.0045% | $4.53 | $6,369 | -0.67% | ||
| 2024-10-01 | Sale | director | 2,431 0.0085% | $4.94 | $12,009 | -6.02% | ||
| 2024-09-04 | Sale | director | 2,431 0.0088% | $5.52 | $13,419 | -16.37% | ||
| 2024-08-01 | Sale | CHIEF EXECUTIVE OFFICER | 2,431 0.0089% | $6.25 | $15,206 | -17.78% | ||
| 2024-07-05 | Sale | director | 1,173 0.0043% | $6.03 | $7,073 | 0.00% | ||
| 2024-07-02 | Sale | CHIEF EXECUTIVE OFFICER | 2,431 0.0091% | $6.13 | $14,902 | 0.00% | ||
| 2024-06-03 | Sale | CHIEF EXECUTIVE OFFICER | 2,431 0.0089% | $6.76 | $16,434 | -18.60% | ||
| 2024-05-01 | Sale | CHIEF EXECUTIVE OFFICER | 2,431 0.009% | $9.11 | $22,152 | -37.00% | ||
| 2024-04-22 | Sale | CHIEF OPERATING OFFICER | 22,223 0.0814% | $9.32 | $207,029 | -38.17% | ||
| 2024-04-19 | Sale | CHIEF OPERATING OFFICER | 22,222 0.082% | $9.34 | $207,442 | -37.47% | ||
| 2024-04-18 | Sale | CHIEF OPERATING OFFICER | 44,444 0.1022% | $5.96 | $265,108 | -38.57% | ||
| 2024-04-17 | Sale | CHIEF OPERATING OFFICER | 44,444 0.1033% | $6.11 | $271,553 | -38.87% | ||
| 2024-04-16 | Sale | CHIEF OPERATING OFFICER | 44,444 0.1006% | $6.29 | $279,722 | -41.88% | ||
| 2024-04-15 | Sale | director | 800 0.003% | $10.45 | $8,360 | -41.67% | ||
| 2024-04-15 | Sale | CHIEF OPERATING OFFICER | 44,444 0.1001% | $6.30 | $280,126 | -41.67% | ||
| 2024-04-05 | Sale | CHIEF EXECUTIVE OFFICER | 44,300 0.1644% | $10.75 | $476,269 | -41.53% | ||
| 2024-04-04 | Sale | CHIEF EXECUTIVE OFFICER | 44,283 0.1632% | $10.89 | $482,400 | -42.62% | ||
| 2024-04-03 | Sale | CHIEF EXECUTIVE OFFICER | 40,584 0.1499% | $10.78 | $437,451 | -41.78% | ||
| 2024-04-01 | CHIEF EXECUTIVE OFFICER | 29,167 – | $0 | $0 | -42.16% |
Insider Historical Profitability
| Andrade Robert | CHIEF FINANCIAL OFFICER | 104271 0.3802% | $5.34 | 1 | 10 | |
| Raykov Rosty | director | 66432 0.2422% | $5.34 | 1 | 15 | |
| Butts Robert W | 41504000 151.3215% | $5.34 | 1 | 0 | ||
| Southpoint Capital Advisors LP | 10 percent owner | 4077214 14.8653% | $5.34 | 3 | 1 | +14.67% |
| Essetifin SPA | 10 percent owner | 3993694 14.5608% | $5.34 | 2 | 0 | +12.47% |
Institutional Investor Ownership
| Southpoint Capital Advisors Lp | $45.34M | 14.92 | 4.08M | 0% | +$0 | 0.9 | |
| Sonic Gp Llc | $26.77M | 8.81 | 2.41M | 0% | +$0 | 35.88 | |
| DG Capital | $16.81M | 5.53 | 1.51M | +40.54% | +$4.85M | 10.88 | |
| Solas Capital Management Llc | $12.35M | 4.06 | 1.11M | -19.46% | -$2.98M | 7.94 | |
| The Vanguard Group | $11.27M | 3.71 | 1.01M | -11.09% | -$1.41M | <0.0001 |